Galera Therapeutics Gets Orphan Drug Designation for Rucosopasem
18 Mai 2023 - 2:44PM
Dow Jones News
By Chris Wack
Galera Therapeutics said Thursday that the U.S. Food and Drug
Administration has granted orphan drug designation to its second
product candidate, rucosopasem manganese, for the treatment of
pancreatic cancer.
Rucosopasem is a next-generation selective dismutase mimetic in
clinical development to augment the anti-cancer efficacy of
stereotactic body radiation therapy in patients with pancreatic
cancer and lung cancer.
The company is currently conducting a Phase 2b 220-patient trial
of rucosopasem in combination with SBRT in patients with locally
advanced pancreatic cancer.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
May 18, 2023 08:29 ET (12:29 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Galera Therapeutics (NASDAQ:GRTX)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Galera Therapeutics (NASDAQ:GRTX)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024
